Navigation Links
Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
Date:1/19/2011

iable treatment paradigm for cancer," said Mr. Chereau.  

Pervasis' Current Clinical ProgramsPervasis is currently conducting a Phase 1/2 clinical study of PVS-10200, an investigational new drug under development to prevent restenosis in patients with peripheral arterial disease who undergo angioplasty and stent placement in the superficial femoral artery. The company's most advanced program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 trials in patients undergoing arteriovenous access procedures for hemodialysis. In 2010, Pervasis announced that it had reached an agreement with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of Vascugel under the FDA's Special Protocol Assessment (SPA) procedure. Through the SPA procedure, FDA formalized its agreement that the design of the Phase 3 trial was acceptable to support a regulatory submission seeking new drug approval.

About Pervasis Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts -- the failure of which result in serious complications and a significant increase in medical costs. The company's most advanced program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 trials in patients undergoing vascular access for hemodialysis. In addition, Pervasis is pursuing a cell-based oncology program focused on targeting and regulating cell stroma in order to prevent key processes that play a role in advancing solid tumor growth and survival. Pervasis is also applying its platfo
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
2. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
3. PTC Therapeutics President and CEO Elected AAAS Fellow
4. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
5. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
6. Echo Therapeutics to Present at the OneMedForum 2011 Conference
7. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
8. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
9. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN DIEGO, May 5, 2015  Trovagene, Inc. ... today reported its financial results for the three ... "In the first quarter, we presented favorable clinical ... Lung Cancer Conference, demonstrating our Precision Cancer Monitoring ... in pancreatic, colorectal, and lung cancers," said Antonius ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - Ergoresearch ... Laval and known under the « Équilibre, ... closing of the transaction previously announced on April 23, ... and outstanding  shares of Orthoconcept (2008) inc.   ... 000 common shares (TSXV: ERG) to the vending shareholder, ...
(Date:5/5/2015)... , May 5, 2015  Desert Valley Medical Center, named ... is the first U.S. hospital to deploy the wireless ... to help reduce the duration of labor and risk of ... and the risk of caesarean birth is reduced in mothers ... most mothers in labor are given epidurals and tend to ...
Breaking Medicine Technology:Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 2Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 4
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... with VGXI, Inc. (The Woodlands, TX) ("VGXI") to,supply ... consisting,of the Factor 5A gene and siRNA against ... preclinical in vivo results,using its combination siRNA and ...
... ... Professionals, VOORHEES, N.J., July ... disease with a wide spectrum of,severity, ranging from mild diarrhea to ... of patients who develop an initial,case of CDI.(1) These patients are ...
Cached Medicine Technology:Senesco Chooses VGXI to Produce Factor 5A Plasmid 2Senesco Chooses VGXI to Produce Factor 5A Plasmid 3Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2
(Date:5/5/2015)... May 05, 2015 Hiliary Critchley, ... will present at the 24th Annual WEDI ... p.m. MT in Scottsdale, AZ. WEDI, the Workgroup ... nonprofit authority on the use of health IT ... Graf, National Director of Telemedicine for UnitedHealthcare will ...
(Date:5/5/2015)... 2015 From the halls of ... leader in enabling enterprise collaboration across platforms and ... speed up and simplify the move to Microsoft ... Solutions for Office 365 enable organizations to ... sustainable user adoption and effectively managing critical business ...
(Date:5/5/2015)... Sunny skies and cool temperatures made for great conditions ... and walkers participated in Global Lyme Alliance’s (GLA) inaugural ... The 5K and 10K runs and 1-and 3-mile walks were ... funds for tick-borne disease research. The “Lyme Walk and Run” ... of Lyme Research Alliance (LRA) and Tick-Borne Disease Alliance ...
(Date:5/5/2015)... May 05, 2015 " QuickPick Travel ” ... Report, which takes a look small, medium, and large businesses ... for NewsWatch and a business expert, conducted the business review ... to plan up to three weeks of vacation for free. ... and friends, and explore the world. And when people are ...
(Date:5/5/2015)... May 05, 2015 Information ... company serving the federal government, today announced its ... (CCSi). CCSi provides solutions exclusively to federal government ... experience in cyber security, health services, and program ... and industry-relevant credentials as a Third Party Assessment ...
Breaking Medicine News(10 mins):Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 3Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4
... www.harvesttech.com ) announced today that its new patient-education website, ... offer persons who are considering enrolling in the Company’s clinical ... study’s design, the science that underlies it, and the location ... ...
... quality of care for mothers and,babies, WASHINGTON, ... for mothers and newborns the National,Quality Forum endorsed ... received by mothers and babies during the third ... quality,of care by standardizing measurement in care settings ...
... A novel topical therapy for nail fungus, NB-002, ... fungus by penetrating skin pores and diffusing through the ... a study conducted by NanoBio Corporation. , The data ... which resists topical therapies because they cannot penetrate the ...
... buy-back program expects to collect 16 tons of candy, ... consumes more,than 24 pounds of candy per year, and ... For most people, this year,s candy noshing will,simply create ... million,North Americans in orthodontic treatment, Halloween treats can pose ...
... WOODCLIFF LAKE, N.J., Oct. 28 Par,Pharmaceutical Companies, Inc. (NYSE: ... call and live webcast on Friday, November 7, 2008 at ... September 27, 2008.,The Company will release results after the market ... available on the Par website,at http://www.parpharm.com ., Access ...
... announced that despite an overall increase in news reporting ... media coverage has become significantly more negative. "How the ... breast, colorectal and prostate cancer coverage, was an independent ... analyses were issued in 2000 and 2004. The report ...
Cached Medicine News:Health News: Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 3Health News:New topical approach to treating nail fungus circumvents problems with current therapy 2Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 2Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 3Health News:Media coverage of lung cancer is increasing, and increasingly negative, new report shows 2
... An enzyme-linked immunosorbent assay ... detection of IgG-class antibodies to ... test is intended to be ... the diagnosis of gastrointestinal disorders, ...
... assurance reagent in assays detecting IgG and IgM ... IgM), IgG and IgM antibodies to rubella virus ... antibodies to cytomegalovirus (CMV IgG and IgM), and ... types 1 and 2 (HSV-1 IgG, HSV-1 IgM, ...
... a safe, non-surgical process that uses ... skin and reverse the signs of ... to cause collagen contraction while preserving ... addition, Titan can stimulate long-term collagen ...
... XLTEK lets you choose how to configure ... of the study to be performed we ... to your budget and clinical needs. How do ... we listen. The result? Kortex. The system that ...
Medicine Products: